Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call. My name is Sammy and I'll be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad to remove yourself from the question queue. I'd now like to hand over to your host, Alison Way, Senior Vice President of Investor Relations and Corporate Communications to begin. Please go ahead, Alison. Thank you, Sammy. Good morning and welcome, everyone, to the Xeris Biopharma Third Quarter 2025 Earnings Call. You can find this morning's earnings release and our detailed financial results on the investor relations section of our website. Today, I'm joined by John Shannon, CEO, and Steve Piper, our CFO. After our prepared remarks, we'll open the line for questions. Before we begin, I'd like to remind you that this call will contain certain forward-looking statements concerning the company's future expectations plans, projects, and financial performance. Forward-looking statements are subject to risks and uncertainty and could cause actual results to differ materially from those forward-looking statements. For more information on our risks, please refer to our earnings release and risk factors included in our SEC filings. Any forward-looking statements in this call represent our views only as to the date of this call and subject to certain applicable laws. We disclaim any obligation to update such statements. Please note that some metrics we will discuss today are presented on a non-GAAP basis. We have reconciled the comparable GAAP and non-GAAP figures in our earnings relief. I'll now turn the call over to J...